In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer

Randén-Brady, Reija; Carpén, Timo; Jouhi, Lauri; Syrjänen, Stina; Haglund, Caj; Tarkkanen, Jussi; Remes, Satu Maria; Mäkitie, Antti; Mattila, Petri S.; Silén, Suvi; Hagström, Jaana

doi:10.1016/j.humpath.2019.05.006

Cited by 46 publications

(54 citation statements)

References 32 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data from HPV DNA detection, p16 and RNA scope on these patients has also been published elsewhere by Randen-Brady et al [26] (the PM II cohort).…”

Section: Workflow and Data Availabilitymentioning

confidence: 78%

“…p16 INK4a was detected immunohistochemically on FFPE tissue samples on individual slides as previously described [26,27]. Briefly, after deparaffinization and rehydration a pre-treatmentmodule (Lab Vision Corp., UK Ltd., UK) was used for treating the tissue slides in Tris-HCl buffer (pH 8.5).…”

Section: Tissue P16 Ink4a Detectionmentioning

confidence: 99%

“…Firstly, DNA was extracted from 4 to 10 μm diameter sections cut from formalin fixed paraffin embedded (FFPE) tissue sections using the high salt method as described earlier [29]. For HPV genotyping, Multiplex HPV Genotyping Kit1 (DiaMex GmbH, Germany) was used as described earlier [22,26,27]. Primer Set 1 contains all HPV primers: 9 biotinylated forward and 3 reverse primers for amplifying the HPV types under investigation.…”

Section: Tissue Hpv Dna Detectionmentioning

confidence: 99%

“…In situ hybridization (ISH) for high risk HPV E6/E7 mRNA was performed manually using the RNAscope1 2.5 HD Reagent kit (Advanced Cell Diagnostics, Inc., Hayward, CA) according to the manufacturer´s protocol as described also in detail in our recent papers [26,31]. Five-μm formalin-fixed and paraffin-embedded tissue microarray (TMA) sections were incubated for 1 hour at 58˚C to fix the samples onto slides.…”

Section: In Situ Hybridization For High-risk Hpv E6/e7 Mrnamentioning

confidence: 99%

See 3 more Smart Citations

Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background The surrogate immunohistochemical marker, p16 INK4a , is used in clinical practice to determine the high-risk human papillomavirus (HPV) status of oropharyngeal squamous cell carcinomas (OPSCC). With a specificity of 83%, this will misclassify some patients compared with direct HPV testing. Patients who are p16 INK4a-positive but HPV DNA-negative, or RNAnegative, may be unsuitable for treatment de-escalation aimed at reducing treatmentrelated side effects. We aimed to identify cost-effective serum markers to improve decision making for patients at risk of misclassification by p16 INK4a alone. Methods Serum proteins from pre-treatment samples of 36 patients with OPSCC were identified and quantified using label-free mass spectrometry-based proteomics. HPV-status was determined using p16 INK4a /HPV DNA and E6/E7 mRNA. Serum protein expressions were compared between groups of patients according to HPV status, using the unpaired t-test with a Benjamini-Hochberg correction. ROC curves (AUC) were calculated with SPSS (v25).

show abstract

“…The data from HPV DNA detection, p16 and RNA scope on these patients has also been published elsewhere by Randen-Brady et al [26] (the PM II cohort).…”

Section: Workflow and Data Availabilitymentioning

confidence: 78%

Section: Tissue P16 Ink4a Detectionmentioning

confidence: 99%

Section: Tissue Hpv Dna Detectionmentioning

confidence: 99%

Section: In Situ Hybridization For High-risk Hpv E6/e7 Mrnamentioning

confidence: 99%

See 2 more Smart Citations

Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…For non-oropharyngeal SCCs, prevalence of HPV related SCCHN is much lower which makes p16 IHC unreliable. HPV DNA detection by polymerase chain reaction has been regarded as the gold standard, but recently direct visualization using RNA probe (RNA in situ hybridization) has been shown to be highly sensitive and specific in detecting transcriptionally active HPV in oropharyngeal cancers [24].…”

Section: Hpv Detection For Diagnosismentioning

confidence: 99%

Squamous cell carcinoma of head and neck: what internists should know

Jung

Narwal

Min

et al. 2020

Korean J Intern Med

View full text Add to dashboard Cite

Squamous cell carcinoma of head and neck (SCCHN) is a group of cancer arising from mucosal surfaces of the head and neck. Optimal management of SCCHN requires a multidisciplinary team of surgical oncologists, radiation oncologists, medical oncologists, nutritionist, and speech-language pathologists, due to the complexity of anatomical structure and importance of functional outcome. Human papilloma virus (HPV)-related SCCHN represents a distinct subset from HPV negative SCCHN which is associated with carcinogen exposure such as cigarette smoking, betel nut use and alcohol. HPV related SCCHN responds better to concurrent chemoradiation and has better overall prognosis, compared to HPV negative SCCHN. Radiation therapy has been introduced to the treatment of SCCHN, administered concurrently with systemic chemotherapy for locoregional SCCHN, as well as a palliative measure for recurrent and/or metastatic (R/M) SCCHN. Recently, immune checkpoint inhibitors have been shown to improve overall survival in R/M-SCCHN and have been incorporated into the standard of care. Combination approaches with immune therapy and targeted therapy for biomarker enriched population based on genomics are being actively investigated and will shape the future of SCCHN treatment.

show abstract

Neoplasms of the Head and Neck

Ferris¹,

Garden²,

Saba³

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Head and neck cancers (HNCs) comprise a diverse group of malignancies affecting the upper aerodigestive tract. The most common tumor type is squamous cell carcinoma. While the main risk factors for HNC remain tobacco and alcohol abuse, oncogenic viruses such as human papilloma virus and Epstein–Barr virus play a major carcinogenic role in tumors of the oropharynx and nasopharynx respectively. The management of head and neck malignancies is site and histology specific and requires a multidisciplinary team approach. Immunotherapy has become the standard of care in the treatment of advanced metastatic squamous cell cancers. In this article, we will review the current knowledge of HNC, with focus on squamous and salivary cancers, and discuss ongoing and future research aiming to improve the management and outcomes of patients with these malignancies.

show abstract

In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer

Abstract: In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer

Cited by 46 publications

References 32 publications

Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients

Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients

Squamous cell carcinoma of head and neck: what internists should know

Neoplasms of the Head and Neck

Contact Info

Product

Resources

About